Advanced treatment for hypertension | Novant Health

Beyond Pills: The Rising Tide of Renal Denervation and the Future of Hypertension Treatment

For decades, managing hypertension has largely revolved around medication. But a new approach, renal denervation (RDN), is gaining momentum, offering a potential lifeline for those with resistant hypertension – and hinting at a broader shift in how we tackle this widespread condition. Novant Health’s recent adoption of RDN, alongside Medicare and Medicaid coverage starting in late 2025, signals a turning point.

The Challenge of Resistant Hypertension: A Growing Problem

Nearly one in five hypertension patients grapple with resistant hypertension, where blood pressure remains stubbornly high despite trying three or more medications. This isn’t just about inconvenience; it’s about increased risk of heart attack, stroke, and kidney failure. The side effects of multiple medications – fatigue, shortness of breath – can also significantly impact quality of life. RDN offers a potential path to reduce reliance on these drugs.

“We’re addressing a small number of sympathetic nerves around the kidneys to safely and effectively reduce hypertension and lower the risk of heart attack and stroke,” explains Dr. Nizar Noureddine, an interventional cardiologist with Novant Health Cardiology – Kimel Park Main.

How Renal Denervation Works: A Minimally Invasive Solution

RDN isn’t a cure, but a targeted intervention. The minimally invasive outpatient procedure uses ultrasound energy to disrupt the overactive nerves around the kidneys that contribute to high blood pressure. A catheter inserted through the groin delivers these ultrasound vibrations, effectively “resetting” the sympathetic nervous system’s influence on blood pressure. The process takes roughly one to two hours.

Early clinical trials have shown promising results, with reductions in systolic blood pressure ranging from -8 mmHg to -12.1 mmHg sustained for several years. These reductions, while seemingly modest, can translate to significant improvements in cardiovascular health.

Future Trends: Beyond Blood Pressure Control

The potential of RDN extends beyond simply lowering blood pressure. Researchers are exploring its application in other conditions linked to sympathetic nervous system overactivity. Here’s what we can expect to see in the coming years:

• Heart Failure: Studies are investigating whether RDN can improve outcomes in patients with heart failure, particularly those with preserved ejection fraction (HFpEF), where current treatment options are limited.
• Chronic Kidney Disease: The link between hypertension and kidney disease is well-established. RDN could potentially slow the progression of kidney damage by improving blood pressure control and reducing sympathetic nerve activity in the kidneys.
• Obesity-Related Hypertension: Obesity often leads to increased sympathetic nervous system activity. RDN might offer a complementary approach to lifestyle interventions and medication in managing hypertension associated with obesity.
• Personalized RDN: Advances in imaging and physiological monitoring could allow for more precise targeting of renal nerves, tailoring the procedure to individual patient needs and maximizing its effectiveness.
• Combination Therapies: RDN is unlikely to replace medication entirely. The future likely lies in combining RDN with optimized medication regimens and lifestyle modifications for a synergistic effect.

Did you know? The first renal denervation systems received FDA approval in 2023, marking a significant milestone in the field of hypertension treatment.

The Role of Artificial Intelligence and Machine Learning

AI and machine learning are poised to play a crucial role in identifying ideal candidates for RDN. Algorithms can analyze patient data – including medical history, genetic predispositions, and lifestyle factors – to predict who is most likely to benefit from the procedure. This will help avoid unnecessary interventions and ensure that RDN is used effectively.

Challenges and Considerations

Despite the promise, challenges remain. The multifactorial nature of hypertension means that RDN won’t work for everyone. “It’s important for referring physicians to rule out pseudoresistance to treatment – such as nonadherence, secondary hypertension and white-coat effects – prior to referral,” emphasizes Dr. Sunil Iyer, an interventional cardiologist with Novant Health Heart & Vascular in Wilmington.

Furthermore, long-term data is still needed to fully assess the durability of RDN’s effects and identify any potential late complications. Cost and accessibility also remain barriers to widespread adoption.

Who is a Good Candidate for Renal Denervation?

• Confirmed uncontrolled or resistant hypertension
• Adherence to an optimized medication regimen
• Commitment to appropriate lifestyle changes (healthy BMI, low sodium intake, regular exercise)
• Not a candidate for, or unable to tolerate, sufficient antihypertensive medication

Patients are generally excluded if they have significant renal pathology or unfavorable renal artery anatomy.

FAQ: Renal Denervation – Your Questions Answered

Is renal denervation a permanent solution for hypertension?

While RDN can provide sustained blood pressure reductions, it’s not a cure. Lifestyle modifications and medication may still be necessary.

What are the risks of renal denervation?

Risks are generally low and include bleeding, bruising, or infection at the catheter insertion site. There’s also a possibility the procedure won’t lower blood pressure.

How long does the procedure take?

The procedure typically takes one to two hours and is performed on an outpatient basis.

Is renal denervation covered by insurance?

As of late 2025, renal denervation procedures are covered by Medicare and Medicaid.

Pro Tip: Discuss your individual risk factors and treatment options with your physician to determine if renal denervation is right for you.

The future of hypertension treatment is evolving. Renal denervation represents a significant step towards a more personalized and targeted approach, offering hope for those who haven’t found relief with traditional methods. As research continues and technology advances, RDN is poised to become an increasingly important tool in the fight against this pervasive condition.